Drugs / RNL-Vascostem®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01302015 | Dec 2007 → Dec 2013 | thromboangiitis obliterans | R-Bio | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RNL-Vascostem | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01302015 ↗ |
| Modality | Cell therapy | “This drug is an autologous cell treatment for necrosis in the legs of patients with Beurger's diseases to improve symptoms through vascular regeneration.” NCT01302015 ↗ |
| Route | Intramuscular | “Intramuscular infusion, 5 x 10e6 cells/kg” NCT01302015 ↗ |